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ABSTRACT

Over the years, three-dimensional (3D) printing has gradually become more common in
people's lives. Due to its quick development, it has attracted the attention of researchers in the
pharmaceutical industry. The main purpose of this project was to couple fused deposition
modelling (FDM) 3D printing with hot melt extrusion (HME) technology to manufacture tablets
with different drug release profiles and to solve dose issues related to an individual’s
physiological differences and to enhance extended release properties. Ketoprofen was used as the
model drug and different properties were added to the polymer to create a formulation suited to
HME technology for the production of filaments used for printing.
This study also investigated polymer matrices and how 3D printing can affect a drug’s
release into the body.
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1. Introduction
The solid dispersion mainly means that the poorly soluble drug is dispersed in a watersoluble carrier in an amorphous state. For poorly water soluble drugs, solid dispersions have
been shown to significantly improve their dissolution rate, solubility and oral bioavailability. It
improves the wettability of the drug by minimizing the particle size, thereby improving the oral
bioavailability. In this study solid dispersion was obtained through a method called Hot Melt
Extrusion (HME) (Vasconcelos, Sarmento and Costa, 2007; Sareen, Joseph and Mathew, 2012).
HME has been used in the manufacturing process of the plastics industry for a long time, but
only recently has it begun to show great potential in pharmaceutical use. When using the HME
process for the creation of a pharmaceutical dosage, a homogeneous mixture of active
pharmaceutical ingredient (API) and other excipients are rapidly heated and softened in the
extruder and then pressurized into filaments through the die. In addition to improving the oral
bioavailability of API, HME can also be used to develop controlled release drug systems and the
ability to mask API’s bitter taste (Tiwari et al., 2016). HME is an effective technique for
producing solid dispersions, which has great advantages over conventional processes for the high
lipophilicity and poor solubility drugs. The use of HME technology to improve apparent
solubility and dissolution of APIs and drug’s oral bioavailability demonstrate the value of this
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technology as an important drug delivery processing tool (Repka et al., 2007). In recent years,
more and more researchers have attempted to combine HME with 3D printing, and their
achievements have also proved that this novel technology has great potential for development
(Goyanes et al., 2015).
In the traditional sense, three-dimensional printing(3DP) has changed the ink from the normal
printer to thermoplastics. Now the most common 3D printing material is Polylactic Acid (PLA).
PLA is an extremely common synthetic plastic with a low melting point and can be melt processed
at 180°C. There are many factors that affect the use of filaments and 3D printing, but the most
important parameters for evaluating whether a filament suits the production standards of a 3d
printed medicine are the viscosity, stiffness and brittleness of the filament. These aspects are
important during the printing process as filaments with the wrong attributes will often crack or
detach from the 3d printer’s baseplate in such a way that printing cannot be completed. Since most
of the plastics manufacturing industry typically uses PLA in 3d printing, we can use PLA as a
reference to evaluate whether or not our extruded filaments meet the industry standard (Zhang et
al., 2017).
The principle of the fused deposition modelling (FDM) 3D printer is based on a digital model
file, using an adhesive material such as plastic to construct an object by layer-by-layer printing.
Until this layer is completely printed and cured that the next layer can be started. This covering
surface and the curing process are repeated until the object is finished. The first step of 3D printing
is to design the required 3D model by a computer aided design (CAD) program (eg, Autodesk®
2

Fusion 360™) and then convert it to a STL file (Standard Mosaic Language or STereo-lithography)
(Gross et al., 2014). 3d printers have a chamber dedicated to feeding a solid filament into the
extruder; and while it is best to be able to feed continuously, the material can also be fed as a liquid
using a pump. The material should uniform in its preparation so that the chemicals are distributed
evenly in the final tablet form (Gibson et al., 2015). Once in the feeding chamber, the filament is
then heated up to a melting point in a 3D printer which is then pushed through the extruder and
printed as the design designated by the STL file. (Fig. 1).

Figure 1. HME combined with 3D Printing process schematic diagram

Under the Biopharmaceutical Classification System (BCS), drugs that have unit does that
result in low solubility in 250ml of aqueous over a range of pH are classified as Class Ⅱ or Class
Ⅳ (depending on permeability) so they emphasize dissolution as a rate-limiting step for oral
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absorption of BCS Class II and Class Ⅳ drugs (Sareen et al., 2012). According to the existing
guidelines, ketoprofen is a weak acid, belonging to the BCS Class Ⅱ. Because of this, we needed
to improve the solubility of Ketoprofen.
3D printing has many advantages over traditional dosage forms so more manufacturers are
investing in research and development. The first 3D printed prescription drug has already been
successfully marketed in the US. Called Spritam-Aprecia, it was approved by the FDA in 2015
for the treatment of partial epileptic seizures. This new dosage form requires only a little bit
water to allow the tablet to dissolve quickly in the mouth, which also gives people who have
difficulty swallowing more choices (Aprecia Pharmaceuticals, Langhorne, PA, USA).
The gastrointestinal tract is the main limiting factor when looking at the speed of oral
controlled release formulations. And while it is difficult to optimize the formulation to deal with
this factor, it can be done through the control the dissolution process and by guiding the
development and quality of the final product by studying the rate of release of in vitro controlled
release formulations and predicting the rate of release through mathematical models. Drug
dissolution is a complex process and while it is difficult to use a fixed mathematical model for all
the dissolution data, it is possible. Current researchers tend to use some classical mathematical
model to forecast the release for example, zero-order kinetic release model, first-order kinetic
release model, Higuchi model and Ritger - Peppas model. These classic mathematical models are
a big help in analyzing the data.

4

In this research, the intent is to investigate the different types of pharmaceutical polymers to
prepare filaments suitable for 3D printing. The main objectives of this study are as follows: 1)
Using Autodesk® Fusion 360™ to design an original model of the tablet for print. 2) Based on
the physical and chemical properties of the API and polymer, select the appropriate polymers
suitable for 3d printing. 3) Couple HME and FDM 3D Printing to print controlled release tablets
of different densities. 4) Studying the in vivo dissolution release profile of 3D printed tablets.
With the continuous development of the pharmaceutical field, the development of
personalized doses of drugs has received increasing attention. 3D printing technology can meet
the individual needs of people just as compared with traditional pharmaceutical dosage forms
(Jonathan and Karim, 2016).
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2. Materials and Methods
2.1 Materials
Ketoprofen (LGM Pharma, Jersey City, NJ, USA), the chemical used as the model API in
this study, is an arylalkanoic acid compound. It has analgesic, anti-inflammatory and antipyretic
effects, as well as a melting point of around 93-96 ° C. Other chemicals were also studied
alongside the Ketoprofen. These include BenecelTM Hydroxypropyl methylcellulose(HPMC)
K4M, AquaSolveTM Hydroxypropyl methylcellulose (HPMC) -AS HG, and KlucelTM
hydroxypropylcellulose (HPC) LF wich were all donated by Ashland Inc. which is located in
Covington, KY, US.
a)

Methods

2.2.1 Formulations
We created a filament made up of 30% (w/w) Ketoprofen, 50% (w/w) HPMC K4M and
20% (w/w) HPMC- AS HG; we also made another filament with 30% (w/w) Ketoprofen, 50%
(w/w) HPMC K4M and 10% (w/w) HPMC- AS HG 10% HPC LF. Both types of filament were
prepared using a Thermo Fisher Scientific 11 twin-screw co-rotating extruder. Two formulations
and the extrusion conditions were listed in Table 1.
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Table 1. Two different formulations for extrusion.

Formulations

Process
Temperature

Ketoprofen

HPMC-K4M

HPMC-ASHG

w/w%

w/w%

w/w%

(℃)

HPC
LF
w/w%

F1

150

30

50

20

0

F2

150

30

50

10

10

2.2.2 HME Process
The two formulations were mixed as a powder to ensure an even distribution of chemicals
before we applied the HME process. Then a Thermo Scientific™ Pharma 11-mm diameter Twinscrew Extruder (Thermo Fisher, Waltham, MA, US) was used in this study to prepare the
filaments for printing. The formulations were extruded at 150℃ and the screw speed of 50 rpm
in all zones with the standard configuration (Fig. 2). In addition, compared to the standard 3D
Printing filament PLA and the 1.75mm diameter required of the 3D Printer; a 1.5mm round
shape die was chosen to extrude filaments for the next 3D Printing step.
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Figure 2. Standard screw configuration of Thermo Scientific™ Pharma 11-mm diameter Twin-screw Extruder.

2.2.3 Filaments Texture Analysis
A TA-XT2i analyzer (Texture Technologies, Hamilton, MA, USA) was used to test the
filament stiffness in this study. Smooth and even filaments were selected for texture analysis and
each segment was cut 5cm long. In order to better optimize the formulation, we performed a
stiffness test and 3-point bend test. When performing stiffness tests, we set the conditions to a
speed of 2 mm/s and a trigger force of 5.0 g. For the 3-point bending test, we easily found the
breaking force, breaking distance, stiffness and other parameters for each filament. Each of the
filaments was placed on a test bench with a size of 25 mm. The test speed was 10 mm/s with a
trigger force of 5.0 g; this was done at distances of 10.00 mm. Fifteen filaments for each
formulation were tested and data collection and analysis were performed using Exponent
software version 6.1.5.0 (Stable Micro Systems, God-alming, UK).
8

Figure 3. PLA 3-point bending test

2.2.4 Model Design for 3D Printing
Autodesk® Fusion 360TM (Autodesk Inc., USA) was used to design the tablet model we
used in this study. The geometry of the selected dosage form is a tablet consisting of a cylindrical
housing with a similarly shaped core (Figure 4). It was then exported as an STL file to be used
with our printer, an Original Prusa i3 MK3S kit (PRUSA RESEARCH S.R.O. ,Prague, Czech
Republic).
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Figure 4. 3D printing design of shell

2.2.5 Thermogravimetric Analysis (TGA)
Thermogravimetric analysis (TGA) is a thermal analysis method that measures the mass of a
sample as its temperature changes over time. For this study, the samples were tested by using a
PerkinElmer Pyris 1 TGA Thermogravimetric Analyzer (PerkinElmer Inc, Waltham, MA, USA).
By heated the samples from room temperature to 350 ℃ at 10℃/min in an open aluminum pan
and applied ultra-purified nitrogen as a purge gas at a rate of 35 ml /min, data was collected then
analyzed using Pyris software (TA Instruments, LLC, Water, USA).

2.2.6 Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) is a thermal analysis technique. It can measure a
variety of thermodynamic parameters. The mixing powder, filaments, and printed tablets were all
analyzed using DSC. The Diamond DSC system (PerkinElmer, Waltham, MA, US) was used to
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measure and analyze the sample by heating the temperature from 10° C to 200 ° C at 25 ° C /
min with a 5-15 mg sample inside a Tzero Hermetic Aluminum plate. Ultra-purified nitrogen
was used as a purge gas at a rate of 50 mL/min. We collected the data using Pyris software
(PerkinElmer) and analyzed the temperature and the amount of heat transferred per unit time.
2.2.7 Filaments and 3D Printing
We used the prepared filaments to print tablets through a fused deposition modeling (FDM)
3D printer called the Original Prusa i3 MK3S kit (PRUSA RESEARCH S.R.O. ,Prague, Czech
Republic). The tablet core was made using F1(30% (w/w) Ketoprofen, 50% (w/w) HPMC K4M
and 20% (w/w) HPMC- AS HG) and the outside shell was made up of F2(30% (w/w)
Ketoprofen, 50% (w/w) HPMC K4M and 10% (w/w) HPMC- AS HG 10% HPC LF). We then
imported the design into Ultimaker CURA software (version 3.4.1; Ultimaker, Geldermalsen,
The Netherlands) to prepare it for printing.
The printing setting were as follows: printing temperature: 220℃; build plate temperature: 45℃;
layer height: 0.06mm; wall thickness: 0.8mm; wall line count: 2; top/bottom thickness: 0.6mm;
top/bottom layers: 10; horizontal expansion: 0mm; print speed: 60mm/s; build plate adhesion
type: brim.
Table 2. Density gradient modification 3D Printing tablets design
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2.2.8 Scanning Electron Microscopy (SEM)
The cross sections and surfaces of the shell and core of the printed tablet were analyzed
using a JSM-7200 FLV Field-Emission Scanning Electron Microscope (SEM) (JEOL, Peabody,
MA, U.S.). All samples are covered by a gold layer by a gold sputtering system for 30 s at ~ 70
mTorr pressure for visualization. Pictures were then taken by a Canon 60D camera (Canon,
Tokyo, Japan). SEM is critical to our understanding of the internal structure of microscopic
drugs, so we can also get more information about the potential release mechanism of drugs
( Siepmann and Göpferich, 2001).
2.2.9 Tablet Morphology Test
In this study, VWR® Digital Calipers (VWR®, PA, U.S.) were used to get the precise
diameter and height of every tablets, checking each different density combination 5 times. The
12

standard tablet hardness tester (VK200; Agilent Technologies, Santa Clara, CA, USA) was used
to determine the hardness of tablets, and each group was also be measured five times.
2.2.10 In Vitro Drug Release Study
A drug dissolution profile was obtained by the United States Pharmacopoeia (USP)-II
Dissolution Apparatus (Hanson SR8-plusTM; Hansen Research, Chatsworth, Calif., USA) for
3D Printing tablets. The dissolution test was performed according to the United States
Pharmacopoeia standards using a Phosphate Buffer (pH 6.8). Each experiment was performed in
triplicate using 900 mL of the dissolution medium for 24 hours at 37℃ with the paddle speed set
to 50 rpm peddle speed and samples were taken at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 hours and
analyzed. The amount of Ketoprofen released was determined by HPLC (Waters Corp., Milford,
MA, USA) at 246nm using methanol: water as 7:3 as the moving phase and the sample analysis
was performed using Empower software (version 2, Waters Corp.).
2.2.11 Dissolution Mathematical Model Study
An OriginPro 2019 64bit (OriginLab, Northampton, MA, U.S.) was used to analyze and
create the dissolution curve in this study. The previous data from the in vitro drug release was
imported to OriginPro 2019 64bit and choose the non-linear fitting and drawing and analyzing its
relative curve carried out. In this experiment, we investigated the relationship between solubility
and common mathematical release models of dissolution: zero-order kinetic release model, firstorder kinetic release model, Higuchi model and Ritger - Peppas model. By comparing its
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compatibility with various models, the most suitable mathematical dissolution model for
ketoprofen-3D Printing tablets was selected to provide more accurate prediction of dissolution
for future production. Correlation coefficient(R2) was an important parameter in this study to
judge the degree of fit of the model.
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3.
3.1

Results and Discussion

Thermal Analysis
From the TGA result (Fig.5), ketoprofen was been observed start to degrade after 290℃ and

other polymers start degrade around 350℃, so that also means the samples would stay stable
during the HME 150℃ and 3D printing 220℃.
The DSC curves for homogeneous F1 and F2 mixtures without HME process are for the
Core and Shell curves respectively in Figure 6 below. Their DSC curve peaked at about 93℃.
The curves of F1 and F2 after the HME process are the core and shell print shown in the Figure6.
It can be clearly seen that after the heating process, there is no peak in F1 and F2, which shows
that ketoprofen successfully formed homogeneous solid dispersion and achieved the amorphous
state with polymer during the HME process.

15

Figure 5. TGA thermogram for ketoprofen, HPMC- K4M, HPMCAS-HG and HPC-LF

Figure 6. DSC thermogram for F1 and F2 homogeneous mixture and the printed core and shell grinded powder

KlucelTM HPC LF can be an immediate release- tablet binder, and AquaSolveTM HPMC-AS
HG can be a controlled release tablet binder. So when we add AquaSolveTM HPMC-AS HG into
shell's formulation, which has not been included in core formulation, we find some interesting
16

effects. The different formulation design, combined with the difference between internal and
external densities, can make the drugs in the shell release at a different rate, reaching the
minimum effective concentration more quickly. Alongside that, a modified core can help to
maintain a high blood concentration longer. This cascade makes the duration of action of the
drug longer and maintain blood levels within the therapeutic window for a longer period of time.
Two formulations of ketoprofen- loaded filaments were successfully produced through the
HME process. Compared to conventional methods, HME produces filaments which cause the
API and polymer to form an amorphous condition in the molten state, and it squeezes more air
out so that they can be intimately mixed. The lower porosity facilitates the of controlled release
drug, which provides better control of its release curve. HME's extrusion process increases the
hardness of the filaments and reduces the elastic deformation, which can better meet the
requirements of 3D Printing.

3.2 Filament Texture Analysis
During 3D Printing, the filament is wound by a rotatable axle and fed automatically at a
constant speed through a rigid feeding gear. Because of this, the filaments must have certain
properties to work in the feeding system. If the filaments are not hard enough or too brittle or the
viscosity is too low, they will be easily be broken during the feeding process and the printing
cannot be continued. 3D Printing technology is still mainly used in the plastics industry rather
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than pharmaceutical area, so we can compare the filaments we made with standard PLA to judge
whether they are suitable for printing. Viscosity; hardness and brittleness are the most important
parameters to look at when evaluating the compliance of filaments. The ability to deform a
material when it is stressed is called ductility. The properties of the material itself that are hard
and difficult to bend are defined as stiffness, which is when the ductility is low (Rösler et al.,
2007). The stiffness is the key to determining whether the filaments can be successfully fed into
the 3D Printer's feeder, because the filaments are easily broken during this process. According to
physics, the brittleness should be calculated like this formula:
Stiffness= F/ δ
Here, the applied force is F, and deformation is δ. In this study, we think that the breaking
force is applied force, and the breaking distance represents deformation. In 3-point bending test,
the breaking force means the magnitude of the force let filaments break. The breaking distance is
the distance from the filaments start deformation till fracture. Then using these two parameters
we can calculate the stiffness of the filaments. In this study, each group of filaments was tested
and printed ten times. Successful printing for more than six times would be defined as adequate
properties for 3D Printing. According to the previous study, we already chose the filaments good
for printing in this study. As such, both F1 and F2 show good mechanical properties and have
been printed successfully ten times each.
Table 3.

Filaments 3-point bending test and stiffness test results
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Formulation Force

Distance

Stress

Stiffness

(g)

(mm)

(g/mm2)

(g/mm)

PLA

1189±12.62

3.75±0.21 10825.054±366.197 317.6±14.71 adequate

F1

628.78±25.49 8.57±0.96 6933.691±974.492

73.36±28.01 adequate

F2

431.5±9.44

63.46±11.23 adequate

6.8±0.45

7006.152±434.166

Property

Compared with PLA, F1 and F2 require a relatively larger breaking force, and the breaking
distance and stiffness are relatively smaller. This is because F1 and F2 are relatively soft, and the
ductility is not easy to be broken. F1's breaking force and breaking distance are larger than F2
which has added extra HPC LF. It can also be concluded that HPC LF will soften the properties
of the filaments, and HPMC AS-HG has higher stiffness than HPC LF. So HPC LF can only be
added in a small amount to moderate the drug release. If there is too much, the filament cannot
meet the requirements of 3D Printing.

3.3 Tablets Morphology Analysis
As shown in Figure 6, 3D Printing drug can maintain the stability of the print to produce
tablets with specifications. Figure 7 shows the shells from 20% to 30% 40% from left to right. It
can be clearly seen that the outer surface of the lower density shell is more rough, because the
19

lower density of the tablet is less precise. Figure 7b is 40% 50% 60% core from left to right,
because the smaller the outer surface is smoother and less rough, but compared to Figure 7a, the
difference in density can be clearly compared. Figure 7c shows a printed shell on the left and a
core on the right.

20

Figure 7. Difference in size and texture between shell and core
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The SEM pictures of core and shell cross-section of 3D printed tablets show that the tablets are
smooth and have excellent performance. Figure 8 also proved the difference of the 3D printing
densities microscopically. For the outside shell it looked really porous and loose and for the
inside core was much tighter. It can also be seen the layer by layer printing style form the bottom
left one (Fig 8).
It can be seen from Figure 8 that 3D printing has demonstrated the advantages of stable
quality of printed tablets in the pharmaceutical area, which laid the foundation for research
consistency.

Figure 8. SEM 3D structure of T5, with a 30% shell fill and 50% core fill
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The geometric characteristics for 3D printed tablets data (Table 4) shows pretty consistent, it
means the printed tablets had really good stability at size. It can be seen from the data (Table 4)
that due to the special structure of the shell core of the tablet, its hardness mainly depends on the
density of the shell and is independent of the core, hardness would increase with the density
increase. It can be seen from Table 4 that 3D printing has demonstrated the advantages of stable
quality of printed tablets in the pharmaceutical area, which laid the foundation for research
consistency.

Table 4. Geometric characteristics of the 3D printed tablets

Tablets

Diameter(mm)

Height(mm)

Weight(mg)

Hardness(kp)

20%Shell

10.04±0.17

5.07±0.08

337±24

14.4±0.1

10.14±0.32

5.05±0.09

339±30

14.4±0.1

10.08±0.28

5.02±0.05

347±12

14.4±0.1

10.09±0.31

5.11±0.21

332±17

15.3±0.1

40%Core
20%Shell
50%Core
20%Shell
60%Core
30%Shell
40%Core

23

30%Shell

9.98±0.23

5.02±0.06

340±12

15.1±0.2

10.17±0.29

5.17±0.08

351±10

15.1±0.2

10.01±0.09

5.04±0.19

343±18

15.3±0.3

10.05±0.13

5.12±0.25

357±21

15.4±0.2

10.05±0.17

5.15±0.03

347±19

15.4±0.2

50%Core
30%Shell
60%Core
40%Shell
40%Core
40%Shell
50%Core
40%Shell
60%Core

3.4 In vitro drug release study
3D printed tablets of different densities were evaluated by their drug release rates curve. The
3D printed drugs all show good properties in controlled release rates because they have higher
hardness, toughness and stiffness. It can be seen from Figure 9 that the release rate of a 3D
printed drug is significantly slower as the density of the shell and core increases. This shows that
we have successfully used a density gradient difference to produce 3D printed tablets that control
the dissolution rate. The core and shell density is different through a maximum of 20% shell and
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40% core, which makes the dissolution profile optimal. In the previous research, due to the
special nature of 3D printing, the printed structure is very hard and compact, so it is
recommended to try not to let the core have too high density under the condition of model
design, which is not conducive to dissolution.
It is also clear from the dissolution curve that the density is one of the important factors
when determining the dissolution rate of 3D Printing tablets. 3D printing requires only the
change of the parameters in the software to make the operation more simple, fast and intuitive,
and make the process more controllable, which is more conducive to manufacturing more
personalized designs.
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Figure 9. In vitro drug release profiles of tablets T1-T9, 100mg ketoprofen released from the HPMC and HPC
matrix

3.5 Dissolution Kinetic Studies
The in vitro dissolution rate of a drug is an important parameter for determining formulation.
When the dissolution rate of a certain dosage is expressed by a special mathematical function, it
is easier to make a quantitative analysis of the dissolution prediction. Here a model of kinetics is
used, where the drug release (Q(t)) over time is a function of time (t). To better analyze the
dissolution of the drug, the following function is used here for analysis (Costa and Lobo, 2003).
3.5.1 Zero-order Kinetic Release Model
The formula here is: Q(t)=Q0+K0t. Where Q(t) is the release amount of the drug at time t, K0
is the zero-order dissolution rate and it is a constant value, and M0 is the initial amount of the
drug in the solution at the initial state, that is, when t=0 (Vareles et al., 1995).
3.5.2 First-order Kinetic Release Model
This model uses the formula, lnQ(t)=lnQ0+K1*t. It’s equal to Q(t)= Q0*(1-e- K1t), where Q(t)
is the release amount of the drug at time t, K1 is the first-order dissolution rate and. In this
circumstances, the percentage of drugs eliminated per unit time in the body remains constant
(Sweeney and Burnham, 1990).
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3.5.3 Higuchi Model
This formula is: Q(t)= Q0 + KH*t1/2. Where Q(t) is the release amount of the drug at time t, KH is
the drug release rate of Higuchi model and this model is the most common model to describe the
controlled release drug (Gohel et al., 2000; Petropoulos et al., 2012).
3.5.4 Ritger - Peppas Model
The Ritger – Peppas model follows the formula, Q(t) /Q(∞) = ktn. Where Q(t) is the release
amount of the drug at time t, Q is the release amount of drug at time ∞,
K and n are coefficients (Ritger and Peppas ., 1987).
3.5.5 Analysis of the Drug Using Mathematical Models
In this research, the parameters of the relevant fitting equations and other calculations can be
easily calculated by using OriginPro 2019 64bit for the different kinetic release models, zeroorder kinetic release model, first-order kinetic release model, Higuchi model and Ritger -Peppas
model. OriginPro 2019 64bit software can perform a variety of complex data simulation and
numerical analysis and drawing operations. Since the original software directly obtains an
intuitive release curve from the initial data, it can directly observe the data with large dispersion
and better eliminate the experimental error.
OriginPro 2019 64bit was used for data linear and nonlinear fitting, and input of the function
worked successively. Table 5 shows the zero-order kinetic release model(a), first-order kinetic
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release model(b), Higuchi model (c), Ritger - Peppas model(d) and Peppas- Sahlin model, which
were used in OriginPro 2019 64bit for the linear and nonlinear curve fitting. Studying these can
also help us to understand the release of drugs more closely. The release of the drug can be
divided into Fickian and non-Fickian diffusion. When the drug only has Fickian diffusion, the
release rate of the drug is independent of the concentration of the drug, and the diffusion
concentration is only time-dependent with distance. It can be seen from the figure that the firstorder kinetic release model; Ritger-Peppas model fits the curve better than the other 3 models
(Dash et al., 2010; Costa and Lobo, 2001).
When considering the results of Ritger-Peppas equation, it can be seen that the fitting error
at the last moment of cumulative drug release is large, but this can also be explained by the fact
that the standard deviation of the raw data at the last moment is inherently large. The R2 of the
Ritger-Peppas equation also shows a good fit. When n ≤ 0.45, it means that there is only Fickian
diffusion (drug diffusion); when n ≥ 0.89, there is only Case Ⅱ transport (skeletal erosion) and
when 0.45＜n＜0.89, the drug release mechanism called non-Fick diffusion(anomalous
transport). So n is the most important parameter in this equation and we printed 9 groups at
different densities. The fitting results of the tablets all conformed to 0.45<n<0.89, which
indicates that the dissolution process of this drug has both Fickian diffusion and Case Ⅱ
transport. The tablet release is the result of drug diffusion and skeleton dissolution (Ritger &
Peppas, 1987).
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In order to better judge which diffusion dominates in the Ketoprofen-based 3D Printing
tablets, the correction formula of the Ritger-Peppas formula, Peppas-Sahlin model is introduced
here for further calculation. Q(t) /Q(∞) = k1tn1 +k2t2n1, which involves the analysis of several
variables. The model considers both Fickian diffusion (the first term of the equation) and the
Case Ⅱ relaxation (the second term of the equation) contribution. If the release of the drug only
has a Fickian diffusion and the Case Ⅱ relaxation can be completely ignored, the n1 in the
formula is equal to the n in the Rigter- Peppas formula. Therefore, the difference between n and
n1 also proves that the release mechanism of the drug is the result of Fickian diffusion and Case
Ⅱ relaxation coupling. The percentage of drug F released by Fickian diffusion can be calculated
by the following formula: F=1/(1+k2/k1*t^n1).
The ratio of Case Ⅱ relaxation R to F can be calculated by the following formula (Peppas and
Sahlim, 1989; Unagolla and Jayasuriya, 2017): R/F= k2/k1*t^n1.
Table 5. Dissolution kinetic parameters of 3D printing tablets

Zero-order

First-order

Ritger- Peppas

Higuchi

Peppas-sahlin

K0

R2

K1

R2

n

R2

KH

R2

K1

K2

N1

R2

T1

4.22

0.83

0.31

1.00

0.47

0.94

23.23

0.94

0.19

0.07

0.85

1.00

T2

4.54

0.87

0.29

0.99

0.52

0.97

23.97

0.97

0.18

0.05

0.72

1.00

T3

5.21

0.69

0.42

0.95

0.56

0.93

25.18

0.96

0.11

0.04

0.80

0.99
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T4

5.38

0.71

0.26

0.96

0.59

0.96

22.79

0.98

0.12

0.05

0.67

1.00

T5

10.30

0.87

0.51

0.98

0.66

0.98

25.24

1.00

0.11

0.02

0.67

1.00

T6

4.69

0.81

0.32

0.95

0.54

0.98

21.30

0.99

0.13

0.02

0.59

1.00

T7

4.91

0.87

0.19

0.94

0.50

0.99

20.03

0.99

0.12

0.06

0.53

1.00

T8

5.68

0.78

0.50

0.95

0.59

0.94

21.39

0.97

0.10

0.04

0.52

0.99

T9

5.69

0.78

0.49

0.95

0.58

0.94

21.42

0.97

0.09

0.04

0.52

0.99

Because the degradation of drugs is a very complex process as they are affected by not only
physical factors but also chemical factors. Any mathematical modeling method must consider
these processes. Although the Higuchi model is the most frequently used model in controlled
release drug mathematical model fitting, researchers have pointed out that the classical equation
using the Higuchi model is premised and more suitable for ideal conditions. The release of the
drug needs to meet the following conditions (Siepmann & Göpferich, 2001; Zhang et al., 2017):
i.

The initial drug concentration should be much higher than the solubility of the
drug.

ii.

Drug spread is one-dimensional.

iii.

Drug release under pure diffusion control.
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iv.

The swelling or dissolution of the iv polymer carrier is negligible.

Table 5 shows the different mathematical models fitting results, and after compared with the
correction coefficient (R2) we can see the Ritger –peppas , higuchi and peppas –sahlin fits the
drug release more than others. And in all of these 3 model, Peppas-sahlin fits best. Because
Peppas- sahlin is the correction formula of the Ritger-Peppas formula, so we will also get the
diffusion method from it. We can use this equation to accurately predict the dissolution and
release rate of the drug in future, which is of great significance for production.
Based on these prerequisites, the Higuchi model is not suitable for in vitro release of 3D
printing in this study. Since the diffusion of the 3D printed tablet is not one-dimensional but
three-dimensional, the initial drug concentration is not much higher than the solubility of the
drug, and the swell happened during HPMCAS-HG skeleton erosion. Though Higuchi model fits
good in here, it won’t be applicable to describe this release profile.
Table 6. R/F parameters for T1-T9

R/F

T1

T2

T3

T4

T5

T6

T7

T8

T9

1.69

1.52

1.50

1.29

1.21

1.13

1.38

1.20

1.07
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The table shows R/F of all 9 group tablets are greater than 1, so Case Ⅱ relaxation dominates the
dissolution part compared to Fickian diffusion. It can also be concluded that as the density
increases, its dominant position will gradually weaken.
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4.

Conclusion

In this study we successfully produced ketoprofen-loaded filaments and printed them into
designed tablets. At the same time, we successfully used the single-punch method to compress
the tablets and performed a comparison of the in vitro dissolution experiments. Experiments have
shown that the same material has significantly improved the dissolution rate after HME and 3D
Printing process, and the therapeutic window of the drug is larger and better. We also confirmed
that the printing density has a great influence on the dissolution rate of 3D printed tablets by the
dissolution of 3D printed tablets of different density gradients. When the density is greater, the
dissolution is slower; and when the density is lower, and the dissolution can be faster in the
body. The effects of different printing densities on a drug’s rate of release were successfully
summarized by using the mathematical model, which provided data for the rational prediction of
drug’s rate of release in the future.
This research successfully combined 3D printing and HME to produced controlled release
tablets with different densities. This research provides a foundation for the development of
controlled release tablets using combined 3D printing and HME technology thus expanding the
use of this emerging technology for development of more complex pharmaceutical in the future.
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